[New oral anticoagulants in primary care: The general practitioner's point of view]

Area of Science:

• Pharmacology
• Cardiology
• Internal Medicine

Context:

• New oral anticoagulants (NOACs) require careful risk-benefit assessment.
• Management involves clinical evaluation and creatinine clearance monitoring.
• Hemostasis tests are unreliable with NOACs.

Purpose:

• To outline the assessment and management of patients on new anticoagulants.
• To highlight the role of general practitioners in NOAC therapy.
• To emphasize patient-centered decision-making.

Summary:

• Benefit assessment relies on thromboembolism and bleeding risk evaluation, utilizing CHA2DS2-VASc and HAS-BLED scores.
• Patient management includes clinical assessment, regular creatinine clearance measurement, and awareness of unreliable hemostasis tests.
• General practitioners play a key role in preventing drug interactions and reporting adverse events.

Impact:

• Provides guidance for healthcare professionals managing patients on novel anticoagulants.
• Underscores the importance of integrating patient values into treatment choices.
• Contributes to safer and more effective use of new anticoagulant therapies.